Itta MacNevin has been appointed Chief Business Officer of Quibim, the Valencia-based artificial intelligence company specializing in imaging biomarkers for precision medicine. The appointment was announced by Coulter Partners, the executive search firm that conducted the search, on June 2, 2026. MacNevin, who held senior commercial roles at drug discovery services provider Evotec for a decade, will lead Quibim's global commercial strategy including business development, partnerships, and go-to-market execution as the company scales its U.S. presence.
Coulter Partners Managing Partner Ian Coyne said identifying a CBO who understood both digital biomarkers and traditional life sciences was the priority for the search, describing MacNevin as "a rare talent whose commercial rigor and international perspective make her the ideal fit." Ángel Alberich-Bayarri, CEO and Co-Founder of Quibim, said MacNevin's appointment came at "a pivotal moment" as the company expands its global reach and emphasised the board and executive team worked closely with Coulter Partners to identify candidates with "deep scientific pedigree and commercial strength." The search process benefited from Coulter Partners' sector-specific insight into life sciences leadership recruitment.
MacNevin brings more than two decades of expertise in life sciences and commercial strategy. She spent 10 years at Evotec, where she rose to Senior Vice President overseeing business development and commercial strategy across North America, holding roles including Senior Vice President Head of Business Development. Before joining Evotec in April 2015, she spent a decade at drug developer Scynexis starting as a medicinal chemist in February 2005 and progressing to business development leadership roles that drove strategic growth and partnerships from the company's early stages. Throughout her career, she has successfully scaled business development teams to serve global pharmaceutical and biotechnology clients. MacNevin holds a B.S. in Chemistry from the University of Richmond and an M.S. in Organic Chemistry from Emory University, providing both scientific grounding and business acumen.
Quibim, founded in 2015 by Dr. Ángel Alberich-Bayarri and Dr. Luis Martí-Bonmatí, has emerged as a leading innovator in imaging biomarkers and artificial intelligence for life sciences. The company offers AI-powered solutions that enable pharmaceutical companies to predict patient responses to drugs, identify clinical trial candidates, and stratify patients by risk, with products serving oncology, immunology, and neurology. Quibim closed a $50 million Series A financing round in January 2025 led by Asabys and Buenavista Equity Partners, enabling expansion of its U.S. presence beyond its established European operations. The company operates over 170 installations worldwide across prestigious institutions including Mass General Brigham and Stanford, and holds regulatory clearances including FDA 510(k) approval. It maintains strategic partnerships with pharma giants including Merck KGaA and Philips, and experienced 168% quarter-on-quarter growth in patient analyses driven by regulatory approvals and global commercial partnerships.
MacNevin's appointment reflects Quibim's transition from early-stage innovation to scaled commercial operations at a critical inflection point. Her two decades navigating pharmaceutical development partnerships and scaling business development functions positions her to translate the company's technical capabilities into revenue expansion and pharma partnerships, particularly as Quibim pursues its ambitious vision of creating human digital twins and whole-body imaging analysis. The hiring may signal that the Series A funding, closing just four months before MacNevin's appointment, requires a seasoned commercial operator to capture expanding institutional adoption and drive pharmaceutical partnerships essential to justifying the company's valuation and achieving future growth milestones in the increasingly competitive AI-powered medical imaging sector.
